Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study

BACKGROUND: The identification of new biomarkers in autosomal-dominant polycystic kidney disease (ADPKD) is crucial to improve and simplify prognostic assessment as a basis for patient selection for targeted therapies. Post hoc analyses of the TEMPO 3:4 study indicated that copeptin could be one of...

Descripción completa

Detalles Bibliográficos
Autores principales: Arjune, Sita, Oehm, Simon, Todorova, Polina, Gansevoort, Ron T, Bakker, Stephan J L, Erger, Florian, Benzing, Thomas, Burst, Volker, Grundmann, Franziska, Antczak, Philipp, Müller, Roman-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616446/
https://www.ncbi.nlm.nih.gov/pubmed/37915893
http://dx.doi.org/10.1093/ckj/sfad118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616446/
https://www.ncbi.nlm.nih.gov/pubmed/37915893
http://dx.doi.org/10.1093/ckj/sfad118

Ejemplares similares